GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, announced today successful first surgeries using its new Alteon® Monobloc Revision Femoral Stem, which is among three new Exactech revision systems making their clinical debut. Earlier this week, Exactech announced the first clinical experience with its new revision knee system. The company is also piloting a shoulder humeral reconstruction prosthesis.
The Alteon Monobloc Revision Femoral Stem is a press-fit, one-piece tapered, splined titanium hip implant. It can be used with the company’s proprietary InteGrip® acetabular and augment system, which features a three-dimensional, porous ingrowth material, providing surgeons an innovative option for complex primary and revision hip replacement surgery.
Orthopaedic surgeons Jeff Pierson, MD, at the Franciscan St. Francis Health in Carmel, Ind., and Jose Rodriguez, at Lenox Hill Hospital in New York, N.Y., performed the first cases with the hip implant during the past week.
“It was a rewarding O.R. day,” Dr. Pierson said. “We have moved from concept to reality in designing a revision system that merges the functionality of modularity with the simplicity of a monobloc stem.”
According to Dr. Rodriguez, “The system performed exactly how it was designed to perform. The instrumentation was simple and intuitive.”
Exactech Chief Executive Officer David Petty reports that “The new hip stem is one more example of our commitment to improving outcomes for patients undergoing a revision to total joint surgery and a key element of our future growth strategy. We believe that providing a one-piece, distally fixed stem is an important solution to meet the needs of these complex procedures.”
This revision hip stem represents years of collaboration among Exactech engineers and a design team of esteemed surgeons including: Andrew Glassman, MD, of the Division of Adult Reconstructive Surgery at Ohio State University Wexner Medical Center in Columbus, Ohio; Michael Kang, MD, at the Insall Scott Kelly Institute for Orthopaedics and Sports Medicine in New York, NY; Jeff Pierson, MD, with the Franciscan St. Francis Health in Carmel, Ind.; and Jose Rodriquez, MD, at Lenox Hill Hospital in New York, NY.
Exactech reports that pilot launch of the new revision hip stem is underway with full market availability in the United States planned for 2016.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
An investment profile on Exactech may be found: http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up: http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
